Sherwin-Williams to Webcast 2012 Year-End Financial Results Conference Call
Frequency Electronics (FEIM) Q2 FY2013 Financial Results, Year-Over-Year Growth in Revenues
3M Affirms 2012 EPS Expectations and Addresses 2013 Outlook
Pernix Therapeutics to Acquire Somaxon Pharmaceuticals (SOMX) in a $25M Stock-for-Stock Transaction
Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections
SAN DIEGO, Dec. 10, 2012 (CRWENewswire) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for life-threatening infections, announced today that it has reached its enrollment objective of 658 patients in the last of its two Phase 3 clinical trials of tedizolid phosphate (TR-701) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).